Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997016205) ANTITUMOR AGENT
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/016205 International Application No.: PCT/JP1996/003105
Publication Date: 09.05.1997 International Filing Date: 23.10.1996
Chapter 2 Demand Filed: 23.05.1997
IPC:
A61K 38/18 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
18
Growth factors; Growth regulators
Applicants:
NAKAMURA, Toshikazu [JP/JP]; JP
Inventors:
NAKAMURA, Toshikazu; JP
Agent:
HIROSE, Takayoshi; Takahashi Building Kita-sangokan 6th floor 13-3, Nishitenma 5-chome Kita-ku, Osaka-shi Osaka 530, JP
Priority Data:
7/30072824.10.1995JP
Title (EN) ANTITUMOR AGENT
(FR) AGENT ANTITUMORAL
Abstract:
(EN) An antitumor agent containing the $g(a)-chain protein ($g(a)-fragment) of an HGF (hepatocyte growth factor) as an active ingredient. The $g(a)-fragment as the active ingredient functions as an antagonist which specifically inhibits the ability of cancer cells to invade or metastasize by means of HGF. This drug is specifically effective in inhibiting the invasion and metastasis of cells of cancers such as gallbladder and lung cancers, which are highly metastatic and result in a high lethality. It is used as an antitumor agent for cancer therapy, prevention, etc., and is highly useful clinically.
(FR) L'invention concerne un agent antitumoral contenant la protéine chaînes $g(a) (fragment $g(a)) d'un facteur de croissance des hépatocytes (HGF), en tant que composant actif. Le fragment $g(a), composant actif fait office d'antagoniste inhibant spécifiquement la capacité de cellules cancéreuses à envahir des tissus et à former des métastases à l'aide du HGF. Ce médicament est particulièrement efficace pour inhiber l'invasion et la métastase de cellules cancéreuses, par exemple pour empêcher les cancers de la vésicule biliaire et des poumons, où la tendance à former des métastases est très forte et la mortalité très élevée. On utilise ce médicament antitumoral très utile pour le traitement clinique de cancers, leur prévention, etc.
Designated States: CA, US
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)
Also published as:
EP0890361US20060030517CA2235805DK0890361